REX launches the PEPT ETF, offering exposure beyond Eli Lilly and Novo Nordisk as the GLP-1 market h

In the latest trading session, Novo Nordisk (NVO) closed at $38.06, marking a -1.35% move from the p

AbbVie is aggressively diversifying its pipeline to mitigate the revenue impact from its loss of pat

BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform

NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of nea

Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk comman

UBS analyst Michael Yee believes investors prefer Eli Lilly's growth story to Novo Nordisk's turnaro

PhRMA sued the Trump administration over its Medicare drug pricing rule, arguing CMS exceeded its au

Novo Nordisk is rated Buy versus Hold for Eli Lilly, anchored by a compelling valuation discount to

Novo Nordisk (NVO) reached $38.26 at the closing of the latest trading day, reflecting a +1.95% chan

Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock grow

Novo Nordisk rose dramatically because investors were excited after it launched the first GLP-1 weig

Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it

Eli Lilly and shows rapid expansion with metabolic health treatments and high revenue growth. Novo N

Eastern Bank decreased its stake in Novo Nordisk A/S (NYSE: NVO) by 32.8% during the undefined quart

NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical effic

FDA extends review for Novo Nordisk's denecimig over manufacturing remediation. Financial outloo

Novo Nordisk is a leading GLP-1 company, but its portfolio beyond that is limited.  Pfizer hasn't en

Anthropic launches a $100 million academy to train 10,000 AI engineers by 2027 as demand for AI tale

The US FDA has extended its review of Novo Nordisk's experimental hemophilia A drug due ​to ongoing

https://www.globenewswire.com/news-release/2026/10/02/3374048/0/en/novo-provides-update-on-the-denec

Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administ

Novo has improved its pipeline through licensing deals. The recent agreements it has signed could yi

Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle pr

Novo Nordisk maintains high profitability through its specialization in chronic disease management a

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in

Eli Lilly's new data show Foundayo's cardiovascular safety and metabolic benefits, while EloraTZP de

Novo Nordisk's Wegovy significantly reduced liver fat in adults with obesity in a recent post ho

Novo Nordisk today presented post hoc analysis of datafrom a STEP UP trial sub-population with 55 pa

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Novo Nordisk presents data showing CagriSema reduces cravings and weight, while real-world patients

Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 b

Eli Lilly says Zepbound and Foundayo provide superior weight loss and blood sugar control over Novo

Novo’s Ozempic (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events

HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing          Tot

Anthropic’s Claude enzyme discovery claim faces scrutiny after a biologist questioned whether prior

New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care:

Oral GLP-1 weight-loss pills are driving a health-tech boom, but research on their safe use is strug

Novo Nordisk eyes M&A to counter patent cliff risks, and partners with Nanexa for long-acting in

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Viking Therapeutics stock jumps 40% after VK2735 shows sustained weight loss with less frequent dosi

Anthropic and OpenEvidence are giving doctors in nearly 100 poorer nations free access to medical gu

https://www.ft.com/content/00d53ca3-725f-4fa8-b452-cef562a13514?syn-25a6b1a6=1 

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Public Citizen exposes separate government drug deals with Pfizer and Eli Lilly, warning the pacts c

Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

U.S. stocks climbed Monday, led by Nasdaq (+1.77%) and Intel (+10%); communication shares rallied, w

Novo Nordisk targets 2026-2030 growth, and unveils Phase 3 CagriSema results beating Eli Lilly's

U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other